Changzhou Qianhong Biopharma Co Ltd

Qianhong Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company at 153 million yuan, a decline of 40.78% from the same period last year. Total operating revenue was 758 million yuan, down 12.00% year-on-year. Net cash inflow from operating activities was 178 million yuan. The latest gross margin was 53.26%, a decrease of 3.06 percentage points from the same period last year; ROE was 5.58%, a decrease of 4.25 percentage points.

Qianhong Pharmaceutical released its 2026 semi-annual report, achieving operating revenue of 758 million yuan, down 12% year-on-year. Net profit attributable to shareholders of the listed company was 153 million yuan, down 40.78% year-on-year. The company's second-quarter net profit was 68 million yuan, down 20% quarter-on-quarter from 85 million yuan in the first quarter.